Table 4
Clinical outcomes for patients with CBF AML with KIT mutations (exon 8, exon 17, or both) compared with patients with WT KIT
Data are presented for the entire study population and by cytogenetic subtype. CBF AML indicates core binding factor acute myeloid leukemia; WT, wild-type; CR, complete remission; W/D, withdrawn; HR, hazard ratio; SE, standard error; OS, overall survival; EFS, event-free survival; DFS, disease-free survival; and RR, relapse risk.
